Acumen Pharmaceuticals, Inc. ·
ABOS 8-K 2026-09-16
Acumen Pharmaceuticals, Inc. (ABOS) 8-K dated 2026-09-16 — accession 0001628280-26-062137.
Acumen Pharmaceuticals, Inc. (ABOS) is a biotechnology company listed on US.
Acumen Pharmaceuticals, Inc. filed a 8-K on 2026-09-16. Accession 0001628280-26-062137.
This 8-K covers: Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported ABOS revenue for 2023-12-31 was $10.8M. Net income was -$52.4M. Revenue was up 351.1% from 2022-12-31 to 2023-12-31. ABOS currently screens at market cap $73.3M.
Not investment advice. The ABOS SEC hub lists recent forms. The stock page is the research view.